cbdMD, Inc. (AMEX:YCBD) released its first quarter of fiscal 2023 results, revealing net sales of $6.1 million, a decrease of 22% compared to net sales of $7.8 million in the Q4 2022, and a decrease of 35% compared to $9.3 million in the Q1 2022.
Q1 2023 Financial Highlights
IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) provided an update on its transaction with Panaxia Pharmaceutical Industries Israel Ltd. and Panaxia Logistics Ltd., part of the Panaxia Labs Israel, Ltd. group of companies, (collectively, "Panaxia").
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s non-addictive pain product and its epilepsy product candidate.
Forian Inc. (NASDAQ: FORA) announced the sale of its cannabis software subsidiary, Bio-Tech Medical Software, Inc. (d/b/a BioTrack), to Alleaves, Inc., effective February 10, 2023, for a total purchase price of $30
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) announced the expansion of their Good Supply cannabis brand portfolio and the launch of their latest flower campaign.
YourWay Cannabis Brands Inc. (OTCPK:YOURF) (CSE:YOUR) (FSE:HOB) has terminated its contracts with two cannabis brands: Old Pal LLC and Airo Brands, Inc.
Hempacco Co., Inc. (NASDAQ: HPCO), a vertically integrated hemp manufacturing company, announced the pricing of an upsized underwritten public offering of 4.2 million shares of its common stock.